Weight-loss medications like Wegovy and Mounjaro, which are part of a class of drugs called GLP-1 receptor agonists (GLP-1 RAs), have generated significant attention for their effectiveness in promoting weight loss. Clinical trials show that users can lose between 16% and 21% of their body weight. However, these drugs are not universally effective, and a significant percentage of individuals don’t experience the same level of success.
While most participants in clinical trials achieved meaningful weight loss (defined as losing at least 5% of body weight), there were a subset of patients who showed minimal results. These “non-responders” typically lost less than 5% of their body weight, a result that is not considered clinically significant. Studies indicate that between 10% and 15% of clinical trial participants fall into this category. Moreover, anecdotal evidence suggests that up to 20% of people outside of clinical trials fail to respond effectively to these drugs.
The Complex Nature of Obesity and Its Genetic Roots
One key reason for this variance in response lies in the complex, multifactorial nature of obesity. Our understanding of the genetic factors contributing to obesity has evolved considerably in recent years. Research has revealed that genetic variations can play a significant role in determining an individual’s predisposition to obesity. For instance, a 2021 study found that a small portion of the UK population (0.3%) carries a genetic mutation affecting brain circuits that regulate appetite, leading to significant weight gain. This genetic variation can result in an additional 17 kilograms of weight by age 18 for those affected.
Such genetic differences may partly explain why some individuals respond poorly to weight-loss drugs, as their biological makeup could make it more challenging to achieve the same results as others.
How These Medications Work—and Why Support Matters
Understanding how GLP-1 medications work is also essential to grasp why they may not be effective for everyone. When individuals attempt to lose weight through diet and exercise alone, they typically face hunger and fatigue—physiological responses that the body uses to protect its perceived “normal” body weight. For some people, this “normal” weight may fall within the obese range, making weight loss particularly challenging.
These medications, however, work by overriding the body’s natural defense mechanisms, reducing hunger and fatigue, and thereby making it easier to lose weight. But it’s not just the medication that contributes to success. Clinical trials typically involve additional support from dietitians, psychologists, and fitness professionals who guide participants through lifestyle changes. This comprehensive approach maximizes the effectiveness of the drugs.
Outside of clinical trials, however, many people don’t have access to the same level of expert support, which can significantly limit the drugs’ effectiveness. Without guidance on diet, exercise, and emotional well-being, individuals may struggle to maintain the lifestyle changes necessary to achieve the desired weight loss.
Factors Influencing Drug Effectiveness
Researchers have attempted to identify factors that could predict how well a person will respond to weight-loss injections. One common predictor is starting body weight—those with a higher baseline weight tend to experience more substantial weight loss. However, there is still no definitive answer as to why some individuals are non-responders.
The Surge in Demand and Off-Label Use
The media attention surrounding the success of drugs like Wegovy and Mounjaro has led to a surge in demand, not just from people who are clinically obese but also from those who wish to lose a few extra kilograms. In the UK, the National Institute for Health and Care Excellence (NICE) outlines specific criteria for prescribing these drugs: the patient must be obese (with a BMI of 30 or higher) and have at least one obesity-related health condition, such as hypertension or sleep apnea.
Despite these guidelines, there have been reports of off-label prescribing, where individuals who do not meet the official criteria are given these medications. This has resulted in some people losing less weight than they might expect based on clinical trial results, as they have a lower body weight to begin with.
Conclusion: A Valuable Tool with Limitations
Despite the fact that semaglutide and similar drugs do not work for everyone, their introduction has been a game-changer for many individuals struggling with obesity. These medications offer a promising new option for weight loss, particularly when combined with lifestyle changes and professional support. However, it’s important for both healthcare providers and patients to understand that the drugs are not a one-size-fits-all solution, and their effectiveness can vary depending on a range of factors, including genetics, starting body weight, and the level of professional guidance available.
Related Topics:
Will Weight Loss Pills Make the Body Dry and Thin?
